Mergers and acquisitions
DrInfo supports several practice management system providers by delivering information on enrolments, capitation optimisation, population health targets, among others.
WellSky will add Healthify’s SDOH capabilities to its portfolio of healthcare technology tools for providers, payers, health systems and community organizations.
The acquisition is expected to help Komodo expand further into the life science space.
The companies will combine their complementary pathology tools to leverage services for tech-enabled diagnostics, drug discovery and patient care.
Once combined, the company will operate as HeartFlow Group and trade on the NYSE under symbol HFLO.
Apostrophe is able to offer patients oral and topical acne medications.
Valo’s flagship product is its Opal Computational Platform, designed to create a new model for drug discovery.
This addition is expected to help CareDx expand into the medication adherence space.
The acquisition will support Carbon Health’s primary care model, which combines in-person clinics with a virtual care platform.
The company plans to use this M&A to gain a foothold in the Medicare space.